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Abstract
Background: Autologous bone marrow-derived stem cells have been ascribed an important therapeutic role in
No-Option Critical limb Ischemia (NO-CLI). One primary endpoint for evaluating NO-CLI therapy is major
amputation (AMP), which is usually combined with mortality for AMP-free survival (AFS). Only a trial which is
double blinded can eliminate physician and patient bias as to the timing and reason for AMP. We examined
factors influencing AMP in a prospective double-blinded pilot RCT (2:1 therapy to control) of 48 patients treated
with site of service obtained bone marrow cells (BMAC) as well as a systematic review of the literature.
Methods: Cells were injected intramuscularly in the CLI limbs as either BMAC or placebo (peripheral blood). Six
month AMP rates were compared between the two arms. Both patient and treating team were blinded of the
assignment in follow-up examinations. A search of the literature identified 9 NO-CLI trials, the control arms of
which were used to determine 6 month AMP rates and the influence of tissue loss.
Results: Fifteen amputations occurred during the 6 month period, 86.7% of these during the first 4 months. One
amputation occurred in a Rutherford 4 patient. The difference in amputation rate between patients with rest pain
(5.6%) and those with tissue loss (46.7%), irrespective of treatment group, was significant (p = 0.0029). In patients
with tissue loss, treatment with BMAC demonstrated a lower amputation rate than placebo (39.1% vs. 71.4%, p =
0.1337). The Kaplan-Meier time to amputation was longer in the BMAC group than in the placebo group (p =
0.067). Projecting these results to a pivotal trial, a bootstrap simulation model showed significant difference in AFS
between BMAC and placebo with a power of 95% for a sample size of 210 patients. Meta-analysis of the literature
confirmed a difference in amputation rate between patients with tissue loss and rest pain.
Conclusions: BMAC shows promise in improving AMP-free survival if the trends in this pilot study are validated in
a larger pivotal trial. The difference in amp rate between Rutherford 4 & 5 patients suggests that these patients
should be stratified in future RCTs.
Background
Over the last decade there have been major changes in
the therapeutic approach to peripheral arterial occlusive
disease (PAD) resulting in improved outcomes and a
decrease in overall mortality [1]. In a review of an
administrative database (Medicare part B claims) Good-
ney and associates showed a threefold increase in endo-
vascular procedures and a dramatic decrease of 42% in
bypass surgery [2]. This shift to less invasive therapy
was accompanied by a significant 25% decrease in major
lower extremity amputations. Despite this progress there
are a considerable number of critical limb ischemia
patients (CLI), who have exhausted their therapeutic
options- the so called no option CLI group (NOCLI).
Various innovative approaches have been employed in
these patients who are beyond the typical catheter-based
or open surgical techniques. Unfortunately, in rando-
mized controlled trials (RCTs) spinal cord stimulation
and prostaglandin infusion have not led consistently to
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any medium, provided the original work is properly cited.an improved clinical state. Autologous cellular therapy,
however, has been associated with promising results, but
has not undergone extensive and rigorous testing by
randomized control trials.
TASC I/II suggested that the combined endpoint of
amputation-free survival (AFS) was the best outcome
measure to assess patients with CLI [3]. The hallmark
BASIL trial which randomized CLI patients between
angioplasty an open bypass surgery employed AFS as its
primary outcome [4]. Despite the wishes of investigators
to employ different primary endpoints such as improve-
ment in: pain, the clinical status of the limb (Rutherford
score), disease specific Quality of Life (QoL), and the
various surrogate measures of Ankle Brachial Index
(ABI) and Transcutaneous pressure of Oxygen
(TCpO2), AFS has been recommended as the gold stan-
dard. Of the many efficacy outcomes with CLI there has
been little detail from controlled trials on the ultimate
goal of the therapy – the prevention of major amputa-
tion (AMP), which is combined with mortality over time
to provide AMP-free survival (AFS). Except for over-
whelming sepsis the decision and timing for AMP is
both physician and patient driven. Only a trial which is
double blinded for both the treating physician and the
patient can eliminate bias as to the timing and reason
for AMP.
T h ep u r p o s eo ft h i ss t u d yi st od e s c r i b et h e6m o n t h
outcomes for a randomized controlled trial of autolo-
gous bone marrow derived stem cells for no option CLI
patients. The focus of this report will be on the descrip-
tion of the timing of, number of and reason for amputa-
tions in both the treatment and placebo groups from a
pilot trial approved by the FDA. The purpose of this
trial was to examine safety features of bone marrow
derived cells implanted intramuscularly in the limbs of
no-option CLI patients. The control group also under-
went iliac crest puncture, but not withdrawal of cells.
The placebo group received peripheral blood as the
injectate. Since this was a safety study, it was not pow-
ered for efficacy. The safety data, three month data, and
a detailed description of the protocol has been presented
previously [5]. Based on these findings and a review of
the literature the implications for designing a pivotal
trial in no option CLI will be discussed.
Methods
A detailed description of the randomized, double-blinded
controlled trial has been presented previously [5].
Patients
Patients qualified for inclusion if they had chronic, criti-
cal limb ischemia including rest pain (Rutherford class
4) or mild-to-moderate tissue loss (Rutherford 5) and
were not candidates for surgical or endovascular
revascularization. Hemodynamic parameters included
one of the following: ankle pressure < 50 mmHg or ABI
< 0.4; toe pressure < 40 mmHg or TBI < 0.4; or TcPO2
< 20 mmHg on room air.
Exclusion criteria included extensive necrosis of the
index limb making amputation inevitable (Rutherford
class 6); uncorrected iliac artery occlusion ipsilateral to
index limb; lack of Doppler signal in the index limb
(ABI = 0); serum creatinine ≥ 2.0 mg/dL; active infec-
tion requiring antibiotics; active malignancy; or any
hematologic disorder that prevented bone marrow
harvesting.
All patients were ≥ 18 years of age and able to provide
informed consent. All enrolled patients underwent pre-
operative cancer screening and ophthalmologic exami-
nations for proliferative retinopathy.
Marrow aspiration, processing & injection
Patients randomized to the cell therapy group under-
went aspiration of 240 mL of bone marrow from the
iliac crest, and aspirate was then processed into 40 mL
of concentrate using the SmartPReP
®2B o n eM a r r o w
Aspirate Concentrate (BMAC) system (Harvest Technol-
ogies, Plymouth, Massachusetts). This automated, point-
of-care centrifuge system has been previously used for
autologous cell therapy in CLI [6,7]. At the time of IV
placement 10 mL of peripheral blood was withdrawn
from each patient. Patients randomized to the control
group had this blood diluted 3:1 and presented in a syr-
inge for injection. The vascular surgeon made 40 intra-
muscular injections of 1 mL aliquots of either BMAC
(experimental group) or dilute peripheral blood (control
group) into previously identified locations along the
ischemic limb using ultrasound guidance. Procedures
were carried out under local anesthesia and conscious
sedation.
Randomization & blinding
Because the decision to amputate is patient and physi-
cian driven, it may be biased by knowledge of treatment
group; therefore, allocation concealment and blinding of
both patient and treating vascular surgeon were
approached very meticulously in this study. Patients
were centrally randomized to investigational treatment
or placebo in a 2:1 ratio. 48 patients were enrolled with
34 receiving cell therapy and 14 receiving placebo injec-
tions. Study group assignment was revealed in the oper-
ating room after prepping and draping but prior to
marrow harvesting. Subject randomization was revealed
only to the individual performing the bone marrow
aspiration. To maintain blinding of patients, bilateral
iliac punctures were performed on all subjects. Treat-
ment patients had 240 mL marrow aspirated whereas
control patients had 2 mL marrow aspirated. Following
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operation of the centrifuge (control group), the
unblinded physician and study coordinator left the pro-
cedure room and the blinded vascular surgeon and
blinded study coordinator entered. The surgeon was
presented with four syringes for injection without know-
ing its contents. For treatment patients this was 40 mL
of BMAC; for control patients it was 40 mL of diluted
peripheral blood. Effectiveness of blinding was assessed
by querying the patients and clinicians after the proce-
dure and at the conclusion of the study.
Follow up & Outcome measurements
Patients were evaluated at 1, 4, 8, 12 and 26 weeks post-
procedure. Clinical outcomes included amputation status,
Rutherford classification of limb ischemia, and pain as
determined by Visual Analog Scale (VAS). Major amputa-
tions were defined as those occurring above the ankle.
Hemodynamic outcome was evaluated by Ankle Brachial
Index (ABI). Laboratory monitoring of hematology and
blood chemistries was also performed. Ophthalmologic
retinal examination was performed at baseline and 12
weeks in diabetics to evaluate for proliferative retinopathy.
Literature review
To define a baseline amputation rate in No Option CLI,
we reviewed the literature for clinical trials of No
Option CLI patients and identified the control groups as
a surrogate natural history population. We queried the
PubMed and the Cochrane database using terms such as
“critical limb ischemia,”“ amputation,”“ randomized con-
trolled trial,” and non-revascularization treatments such
as “cell therapy,”“ spinal cord stimulation,”“ gene ther-
apy,”“ prostaglandin therapy.” We included only clinical
trials published in the English literature within the last
15 years, excluding case reports and case series of fewer
than 5 patients. We excluded papers concerning acute
limb ischemia, surgical or endovascular revasculariza-
tion, ischemia due to diseases other than atherosclerosis
(such as thromboangiitis obliterans), and trials where
the CLI portion of the patient population could be sepa-
rately evaluated.
Statistical modeling
A bootstrap simulation approach was used to model
results for a future pivotal trial. This involved using data
from the pilot trial as input, modifying certain variables,
and performing simulated trials multiple times to quantify
the odds of obtaining significant results in a larger trial.
Results
Patients & Procedure
Patient baseline characteristics are presented in Table 1.
All patients had atherosclerotic arterial occlusive disease.
Table 1 Patient demographics
BMAC Control Total
Patients 34 14 48
Age (years) 72.5 65.7 69.5
(42 - 93) (52 - 85) (42 - 93)
Male (n) 23 9 32
(7.6%) (64.3%) (66.7%)
Diabetes Mellitus
Type 1 1 1 2
(2.9%) (7.1%) (4.2%)
Type 2 17 5 22
(50.0%) (35.7%) (45.8%)
Type 1 + Type 2 18 6 24
(52.9%) (42.9%) (50.0%)
Renal insufficiency (Cr clearance< 40
mg/dL)
314
(8.8%) (7.1%) (8.3%)
Cardiac disease
Angina 4 3 7
(11.8%) (21.4%) (14.6%)
Myocardial infarction 11 2 13
(32.4%) (14.3%) (27.1%)
Congestive heart failure 7 4 11
(20.6%) (28.6%) (22.9%)
Other cardiac 20 11 31
(58.8%) (78.6%) (64.6%)
Coronary revascularization
Coronary artery bypass 11 2 13
(32.4%) (14.3%) (27.1%)
Coronary angioplasty 5 6 11
(14.7%) (42.9%) (22.9%)
Rutherford class
Rutherford 4 11 7 18
(32.4%) (50.0%) (37.5%)
Rutherford 5 23 7 30
(67.6%) (50.0%) (62.5%)
Ankle brachial index (ABI) 0.46 0.396 0.44
(0.13-
1.23)
(0.17-
0.74)
(0.13-
1.23)
Previous amputation (contralateral)
Major amputation 7 1 8
(20.6%) (7.1%) (16.7%)
Minor amputation 6 2 8
(17.6%) (14.3%) (16.7%)
Previous lower extremity
revascularization
Surgical bypass 23 8 31
(67.6%) (57.1%) (64.6%)
Angioplasty 8 7 15
(23.5%) (50.0%) (31.3%)
Stent 5 6 11
(14.7%) (42.9%) (22.9%)
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slightly greater proportion of patients with tissue loss
(Rutherford 5) than did the control group (67.6% vs
50%) although this difference was not statistically signifi-
cant. All marrow aspiration, processing and limb injec-
tion was accomplished in the operating room at a single
visit. To determine the effectiveness of blinding, patients
and investigators were asked prior to discharge follow-
ing treatment to identify which treatment arm the sub-
ject had been assigned. Collected responses were used
to determine a blinding index which demonstrated suc-
cessful blinding of both patients and investigators, as
reported previously [5].
Safety & Adverse Events
This data was presented previously and will be briefly
summarized here [5]. Bone marrow aspiration was well
tolerated. Study patients experienced a mean decrease in
hematocrit 2.6 percent compared with controls. How-
ever this drop was transient, associated with no hemo-
dynamic instability, and required no specific therapy in
any study patients. Injection of ischemic limbs was asso-
ciated with no evidence of muscle damage, either clini-
cally or by elevation in creatine phosphokinase. No
patient developed acute kidney injury. No patient devel-
oped inappropriate angiogenesis such as vascular mal-
formations or arteriovenous fistulae in the index limb or
remote sites. Four patients demonstrated proliferative
retinopathy at screening, but there were no cases of new
or worsened retinopathy at follow up. There were no
cases of new or recurrent malignancy identified during
follow up.
Median follow-up
The median follow up for the 48 patients in this series
was 346 days (range 8 - 783 days). This report will focus
on the six month data. No patients were lost to follow up.
Amputation 6 months
Fifteen amputations occurred within the six month fol-
low up period. One late amputation was performed at
388 days into the trial and was not included in the six
month analysis. At six months, the 10 of 34 patients in
the BMAC group had undergone amputation (29.4%)
while the control group had 5 of 14 patients amputated.
(35.7%) (p = 0.412). (Table 2) When evaluating the
amputation rate by Rutherford classification in all
patients, the Rutherford 4 group had 1 amputation,
while the Rutherford 5 group had 14, irrespective of
treatment group, (5.6% vs 46.7%, p = 0.0029). During
the six month period 93.3% of all amputations per-
formed occurred in the Rutherford 5 group. Within the
Rutherford 5 group, 9 of 23 BMAC patients (39.1%)
underwent amputation as compared to 5 of 7 control
patients (71.4%) (p = 0.1337). (Table 3). Of the 15
amputations, 86.7% occurred within 4 months.
Indications for amputation
Table 4 presents the indications for amputation. Most
patients presented with multiple indications. Pain was
an indication in 13 of 15 amputations, and 7 of these
patients scored a maximum 100 on the VAS pain scale.
Six month mortality
There were two deaths during the 6 month period. One
B M A Cp a t i e n td i e d .O n ec o n t r o lp a t i e n td i e df o l l o w i n g
Table 2 Six month amputation rate by Rutherford class
AMP Tot % AMP p *
All Pts 15 48 31.3%
R4 1 18 5.6% 0.0029
R5 14 30 46.7%
BMAC 10 34 29.4%
R4 1 11 9.1% 0.0721
R5 9 23 39.1%
Control 5 14 35.7%
R4 0 7 0.0% 0.0053
R5 5 7 71.4%
* p calculated using Fischer’s exact test
Table 3 Six month amputation rate: BMAC vs Control,
Rutherford 5 only
R5 AMP Tot % AMP p *
BMAC 9 23 39.1% 0.1337
Control 5 7 71.4%
* p calculated using Fischer’s exact test
Table 1 Patient demographics (Continued)
Atherectomy 2 4 6
(5.9%) (28.6%) (12.5%)
Reason for no option status
Failed revascularization 18 6 24
(52.9%) (42.9%) (50.0%)
Anatomic poor candidate 31 12 43
(91.2%) (85.7%) (89.6%)
Medical high risk 5 1 6
(14.7%) (7.1%) (12.5%)
Other 1 1 2
(2.9%) (7.1%) (4.2%)
Medication
Cholesterol lowering agent 24 11 35
(70.6%) (78.6%) (72.9%)
Beta blocker 15 5 20
(44.1%) (35.7%) 41.7%)
Antiplatelet agent 28 14 42
(82.4%) (100.0%) (87.5%)
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of AFS.
Time to amputation and Amputation free survival
The median time to amputation was 88.5 days in the
BMAC group and 55.0 days in the control group (p =
0.358). Time to amputation is presented as Kaplan-
Meier curves in Figures 1 &2 comparing the impact of
BMAC treatment on all patients (Figure 1) and just
Rutherford 5 patients (Figure 2). Kaplan-Meier curves
for amputation free survival in all subjects (Figure 3)
and Rutherford 5 patients only (Figure 4). Looking at
patients with tissue loss only, the separation of treat-
ment and control curves is more apparent, demonstrat-
ing a modest treatment effect. For amputation, the Log
rank p value is 0.067, for AFS the Log rank p value is
0.123. Patients with tissue loss had a lower AFS than
those without (50.0% vs 94.4%, p = 0.0016)
Regression analysis of patient factors on Amputation rate
& AFS
Using a logistic regression model, we analyzed the effect
of diabetes, age > 75 years, and tissue loss on amputa-
tion rate and AFS. While diabetes and age were not
found to correlate with either outcome, tissue loss had a
statistically significant correlation with both amputation
at 6 months (Odds Ratio 18.48, p = 0.0103) and ampu-
tation free survival (OR 20.15, p = 0.0078).
Change in Rutherford Class
We evaluated change in Rutherford class using a binary
approach. Patients who improved at least one numeric
category (e.g., 5 ® 4) were defined as improved. Patients
who failed to improve or deteriorated at least one class
were defined as worse; amputation was scored as dete-
rioration of Rutherford Class: stable or worsening
Rutherford class. (See Table 5) The overall rate of
improvement was 35.4%, but when evaluated by baseline
category, the difference in improvement rates was statis-
tically significant. For all patients, 66.7% of Rutherford 4
patients improved while only 16.7% of Rutherford 5
Table 4 Indications for amputation
N % Amps
Pain 13 86.67%
Gangrene 6 40.00%
Disease progression 5 33.33%
Local infection 5 33.33%
Systemic infection 1 6.67%
Failure to heal 1 6.67%
Osteomyelitis 0 0.00%
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Figure 1 Time to Amputation over 1 year BMAC vs. Control
(All study patients). The Kaplan-Meier curve demonstrates the
time to amputation over 1 year between BMAC and control
patients in all study subjects.
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Figure 2 Time to Amputation over 1 year BMAC vs. Control
(Rutherford 5 patients only). There were no amputations in the
Rutherford 4 group, removing these patients results in separation of
the BMAC and control curves and demonstrates a trend towards a
positive treatment effect on amputation. (p = 0.067)
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Figures 3 Amputation Free Survival over 1 year BMAC vs.
Control (All study patients). The Kaplan-Meier curve demonstrates
Amputation Free Survival (AFS) over 1 year in all study subjects with
a negligible difference between BMAC and control.
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Rutherford 4s improved than Rutherford 5s (81.8% vs
17.4%, p = 0.0003) Looking at the effect of treatment on
Rutherford 4 patients alone, 81.8% of the BMAC
patients improved while 42.9% of control patients
improved (p = 0.0874).
Change in ABI
Mean change in ABI by treatment group was not signifi-
cant and such analysis is hampered by patients lost to
amputation and missing data points We therefore evalu-
ated ABI in a binary fashion with improvement defined as
increase in ABI ≥ 0.1 per TASCII. Failure to improve was
defined as failure to increase ABI by at least 0.1, decrease
in ABI, amputation or death. Missing data was also
counted as failure to improve. While overall Rutherford 4
patients demonstrated a greater degree of improvement
than Rutherford 5 patients, this was not significant. There
was no difference between treatment and control. This
analysis was complicated by multiple missing data points.
Effect of tissue loss on power calculations
The event rate in Rutherford 4 patients is significantly
less than that in Rutherford 5 patients. We conducted a
sensitivity analysis to determine the impact of increasing
proportions of Rutherford 4 patients on the power cal-
culations to identify a treatment effect on amputation
rate in a pivotal study.
Bootstrap simulation
A bootstrap approach was used to simulate data 1,000
times, using the event rate of AFS component events
(AMP + mortality) in the pilot trial. Given the low ampu-
tation rate in rest pain patients, we limited the simulation
to Rutherford 5 patients (BMAC 43.5%, control 71.4%). A
Cox proportional hazard model was used for analysis of
140 BMAC treated patients and 70 placebo treated
patients. Using this approach 974 out of 1,000 simula-
tions resulted in a statistically significant treatment effect
(p < 0.05). The results indicate a 97.4% chance of show-
ing a statistically significant treatment effect extrapolat-
ing from pilot data in patients with tissue loss.
Amputation rate in the No Option CLI literature
We identified 8 studies in the literature that presented 6
month amputation rates in NOCLI patients. One trial
was a retrospective review of 5 years of unreconstruct-
able CLI patients at an academic medical center with 1
year follow up [8]. The remaining papers were rando-
mized, controlled trials: three spinal cord stimulation
studies [9-11]; one pharmacologic trial of a prostaglan-
din E1 analog (CIRCULASE) [12]; two gene therapy
trials of NV1FGF (TALISMAN [13] and TAMARIS [14];
and one cell therapy trial [15]. To this group we added
the data from the current BMAC cell therapy trial.
Using only the control groups from these trials, we
identified an overall six month amputation rate of 23.0%
in this surrogate natural history population of NOCLI.
(Table 6)
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Figure 4 Amputation Free Survival over 1 year BMAC vs.
Control (Rutherford 5 patients only) displays. The separation of
AFS curves demonstrates a tread towards a positive effect of BMAC
on AFS (p = 0.123). As in Figure 1, the event rate in Rutherford 4
patients was low, diluting any apparent treatment effect.
Table 5 Change in Rutherford class at 6 months
Improved Worse % Imp Total p *
Total 17 31 35.4% 48
R4 12 6 66.7% 18 0.0005
R5 5 25 16.7% 30
BMAC 13 21 38.2% 34
R4 9 2 81.8% 11 0.003
R5 4 19 17.4% 23
Control 4 10 28.6% 14
R4 3 4 42.9% 7 0.2367
R5 1 6 14.3% 7
* p calculated using Fischer’s exact test
Table 6 Six month amputation in NO-CLI Control groups
only
N Amp N Amp %
Jivegard 1995 26 10 38.5%
Lepantalo 1996 136 53 39.0%
Klomp 1999 60 20 33.3%
Amann 2003 39 15 38.5%
Brass 2006 190 16 8.4%
Nikol 2008 56 16 28.6%
Hiatt 2010 259 44 17.0%
Powell 2011 24 6 25.0%
Benoit 2011 14 5 35.7%
804 185 23.0%
NO-CLI: No option critical limb ischemia
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amputation rate we performed a meta-analysis of three
studies that compared amputation rate between patients
with rest pain and those with tissue loss [10,12]. These
trials comprised 264 patients, 114 with rest pain and
150 with tissue loss. Taken together, these trials demon-
strate that tissue loss correlates with an increased ampu-
tation risk. (Table 7)
Discussion
This randomized, double-blinded, controlled trial of auto-
logous stem cell therapy for critical limb ischemia was a
pilot trial and intended to present a safety profile for the
technique and to identify trial design issues for a pivotal
trial. Although not powered to demonstrate efficacy, the
outcomes provide valuable trends about future trial design,
not only for this technique, but for other trials in CLI.
There was a trend toward improved amputation rates
in Rutherford 5 patients treated with BMAC, although
this did not achieve statistical significance. (p = 0.1337)
More important was the difference in amputation rates
between those patients with rest pain at screening
(Rutherford 4) and those with tissue loss (Rutherford 5).
Patients with tissue loss demonstrated a much higher
amputation event rate (46.7%) than did those with rest
pain alone (5.6%) and this difference was statistically sig-
nificant (p = 0.0029). Only a single patient with rest
pain underwent an amputation by six months; patients
with tissue loss at screening accounted for 93.3% of all
amputations. This association was further confirmed by
logistic regression modeling which demonstrated the
correlation of tissue loss with amputation with an Odds
Ratio of 18.48 (p = 0.013).
With regard to change in Rutherford class as an instru-
ment to measure effectiveness of CLI therapy, we found
the opposite. A higher percentage of Rutherford 4 patients
demonstrated an improvement in Rutherford classification
than did Rutherford 5 patients. This makes biologic sense,
because an ischemic ulcer requires more blood flow to
heal than intact skin does to survive. Therefore salvaging a
limb with tissue loss requires a far greater degree of perfu-
sion than does achieving resolution of rest pain [3]. While
change in Rutherford class may be a used to evaluate ther-
apy in patients with rest pain, it may not be as appropriate
for advanced CLI patients.
ABI was a difficult endpoint to evaluate because of
multiple missing data points and the difficultly of incor-
porating amputation into this measure. Hemodynamic
endpoints may not be appropriate for NOCLI patients
at high risk for amputation.
Since the results in our pilot trial differed depending
on the Rutherford classification of patients at screening,
we surveyed the literature for evidence of the impact of
tissue loss on the amputation rate. To determine the
amputation rate in no option CLI patients overall, we
identified a group of NOCLI patients gathered from the
control groups of eight randomized trials and one obser-
vational study in the literature. This surrogate natural
history population demonstrated a six month amputa-
tion rate of 23%. However, only the CIRCULASE trial,
Klomp’s spinal cord stimulation trial and the current
BMAC pilot trial present amputation data according to
Rutherford class. Meta-analysis of these trials demon-
strated that patients with tissue loss have a higher
amputation rate than those with rest pain (Hazard Ratio
8.650, p = 0.0513). This is further supported by a sepa-
rate analysis of patients in a spinal cord trial in which
those with tissue loss demonstrated a higher amputation
risk (HR 2.38, p = 0.018) [16].
Because most published clinical trials group all CLI
patients together regardless of disease severity, it is diffi-
cult to quantify the impact of tissue loss on amputation
rate. However, there is evidence to support that tissue
loss in CLI correlates with poor outcomes. In addition
to an analysis of NOCLI studies, risk stratification mod-
els underline the correlation between tissue loss and
amputation in patients undergoing surgical or endovas-
cular revascularization. The first of two validated risk
stratification models, the PREVENT III tool was derived
from a multivariate analysis of nearly a thousand CLI
patients, and it identified tissue loss as second only to
dialysis as a factor negatively impacting AFS. In a popu-
lation of patients undergoing surgical bypass, tissue loss
was associated with a hazard ratio of 2.2 for increased
risk of death or amputation at one year [17]. The Finn-
vasc model identified tissue loss as a predictor of nega-
tive outcome during the immediate postoperative period
[18]. Worse scores on either of these tools correlate
with decreased AFS at one year in patients undergoing
revascularization [19].
Tissue loss correlates with a variety of poor outcomes
in CLI. Khan et al. demonstrated that in patients under-
going surgical revascularization, tissue loss is associated
w i t hah i g h e rr a t eo fa m p u t a t i o ne v e ni ft h e
Table 7 Six month amputation rates by Rutherford class
Rest pain/R4 N Amp N Amp %
Brass 2006 88 3 3.4%
Klomp 1999 19 3 15.8%
Benoit 2011 7 0 0.0%
114 6 5.3%
Tissue Loss/R5 N Amp N Amp %
Brass 2006 102 12 11.8%
Klomp 1999 41 16 39.0%
Benoit 2011 7 5 71.4%
150 33 22.0%
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anatomic success but functional failure [20]. Nguyen et
al. found that in patients undergoing surgical bypass
those with tissue loss required increased resource utili-
zation such as length of stay and experienced a higher
rate of graft related events (GRE) such as thrombosis,
need for revision or amputati o n[ 2 1 ] .I nap r o s p e c t i v e
observational study of 1560 CLI patients, of whom
36.5% underwent revascularization, Bertele et al. found
that tissue loss was associated with increased risk of
amputation at six months (7.8% vs. 13.9%) [22]. Taylor
et al. reviewed 2240 limb revascularizations for PAD
according to preoperative indication [23]. The popula-
tion included patients with claudication (999), ischemic
rest pain (464), and tissue loss (777). There were signifi-
cant differences in multiple endpoints, including limb
salvage and survival, among the groups. The 1 year limb
salvage rate for patients with rest pain was 88.6% while
for those with tissue loss it was 75.1% (p < 0.001). The
survival rate at one year was 79.1% for rest pain and
65.8% for tissue loss (p < 0.001).
Implications for trial design
This difference in outcomes between patients with tissue
loss and those with rest pain has implications for study
design in CLI. Patients with tissue loss demonstrate a
higher rate of amputation, which is a component of
amputation free survival (AFS). If amputation rate or
AFS are used as the primary endpoint in a clinical trial,
the lower number of amputations in Rutherford 4
patients may dilute the event rate in the overall patient
population making it difficult to demonstrate a treat-
ment effect. This is supported by sensitivity analysis
which demonstrates that increasing the proportion of
Rutherford 4 patients in the study population requires
increasingly larger sample sizes to maintain appropriate
statistical power. Patients with tissue loss are appropri-
ately evaluated using amputation or AFS as an endpoint.
On the other hand, if the outcome measure is change
in Rutherford class, which has been suggested by some
as component of a combined endpoint, a sample
weighted towards Rutherford 4 may better demonstrate
changes by this measure.
Recently some authors have begun to question
whether grouping all CLI patients together obscures the
evaluation of therapy [23-25] and our findings confirm
that patients with tissue loss should be analyzed sepa-
rately from those with rest pain.
Conclusions
Our experience with a pilot trial of cell therapy and a
review of the literature suggest that CLI patients with
rest pain behave differently than those with tissue loss.
If amputation or amputation free survival are to be used
as primary endpoints for CLI trials, study subjects
should be stratified by Rutherford class or limited only
to Rutherford 5 patients in order to best demonstrate a
treatment effect of therapy.
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